Welcome to our dedicated page for Nasus Pharma Ltd. SEC filings (Ticker: NSRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nasus Pharma Ltd. (NSRX) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer listed on the NYSE American. Nasus Pharma files reports with the U.S. Securities and Exchange Commission that include current information on its clinical programs, financial condition, governance, and material agreements.
Nasus Pharma submits current reports on Form 6-K, which have covered topics such as condensed unaudited interim financial statements and management’s discussion and analysis for specified periods, leadership appointments, clinical trial milestones, and collaboration agreements. For example, Form 6-K reports have described the appointment of an Executive Vice President and Chief Financial Officer, the initiation of a Phase 2 clinical study of NS002 with first participant dosed, and expanded agreements with Aptar France S.A.S. and AptarGroup, Inc. to support the intranasal epinephrine program.
Filings also document capital markets events, including the registration and completion of Nasus Pharma’s initial public offering on Form F-1 and subsequent updates on the partial exercise of the underwriters’ over-allotment option. These disclosures outline the company’s stated use of proceeds, such as funding further development of its intranasal epinephrine program and general corporate purposes, and provide detail on underwriting arrangements.
As a foreign private issuer, Nasus Pharma is required to file an annual report on Form 20-F, and it supplements this with periodic Form 6-K submissions when it releases press statements or corporate presentations that are material to investors. Some 6-K filings incorporate press releases, such as the CEO’s letter to shareholders or news of regulatory clearances, directly as exhibits.
On this page, users can review Nasus Pharma’s SEC filings as they are made available through the EDGAR system. Stock Titan enhances access by pairing filings with AI-powered summaries that help explain key sections, highlight clinical and financial themes, and make lengthy documents such as financial statements and management analyses easier to understand. Investors can quickly identify filings related to clinical progress of NS002, leadership and governance changes, capital raising activities, and significant collaboration agreements.
Nasus Pharma Ltd. reported positive interim results from its Phase 2 study of NS002, an intranasal epinephrine powder being developed to treat anaphylaxis. In 25 evaluated participants, NS002 achieved a higher mean peak epinephrine plasma concentration of 655 pg/ml versus 548 pg/ml for EpiPen® and reached peak levels in 10.8 minutes compared with 15 minutes for EpiPen®.
Notably, 91% of participants given NS002 reached the 100 pg/ml epinephrine threshold at 5 minutes, versus 67% with EpiPen®, and early exposure over the first 10 minutes was higher with NS002 (AUC 55 h*pg/ml vs. 32 h*pg/ml). NS002 was well-tolerated in all 50 subjects who completed all treatment arms, with no serious adverse events and mostly mild, local effects, and its effects on blood pressure and pulse were comparable to EpiPen®. Nasus expects full Phase 2 results by the end of the first quarter of 2026 and plans to start a pivotal study in the fourth quarter of 2026.
Nasus Pharma Ltd. (NSRX) announced that it has appointed Eyal Rubin as its new Chief Financial Officer and Executive Vice President, effective November 19, 2025. The company entered into an Employment Agreement with him on the same date and expects to provide its standard indemnification agreement, similar to those for other directors and executive officers. The company states that there are no related party transactions involving Mr. Rubin that require disclosure. Mr. Rubin brings extensive experience from prior CFO roles at Protalix BioTherapeutics and BrainStorm Cell Therapeutics, and treasury leadership roles at Teva Pharmaceutical Industries. Nasus Pharma also issued a press release on November 20, 2025 announcing his appointment.
Nasus Pharma Ltd. reported that it has begun a Phase 2 clinical study of its product candidate NS002, with the first participant already dosed. This step marks a move into a more advanced stage of human testing, where the company will further evaluate NS002’s performance and safety in patients. The update was provided through a press release dated November 18, 2025, which is attached to this report as an exhibit.
Nasus Pharma Ltd (NSRX): Schedule 13G filed — Dr. Ronnie Hershman reported beneficial ownership of 1,383,512 ordinary shares, representing 15.3% of the class. The filing attributes 891,187 shares to Hershman Holdings LLC (managed by Dr. Hershman) with sole voting and dispositive power; 429,307 shares are held by Phoenix Solutions Ltd., where he may be deemed to share voting and investment power; and 63,018 shares are issuable upon exercise of options exercisable within 60 days.
For Hershman Holdings LLC alone, the filing shows 891,187 shares (9.9%) with sole voting and dispositive power. The percentages are based on 9,014,105 ordinary shares outstanding as of September 30, 2025.
Nasus Pharma Ltd. (NSRX) reported a significant shareholder on Schedule 13G. Dr. Dalia Megiddo beneficially owns 1,888,873 ordinary shares, representing 20.9% of the class. She holds sole voting and sole dispositive power over all reported shares.
The percentage is based on 9,014,105 ordinary shares outstanding as of September 30, 2025, as advised to the reporting person. The filing relates to ordinary shares (CUSIP M7071P109).
Nasus Pharma Ltd. (NSRX): Udi Gilboa filed a Schedule 13G reporting beneficial ownership of 1,901,311 ordinary shares, representing 21.1% of the class. He holds sole voting and sole dispositive power over all reported shares, with no shared voting or dispositive power.
The percentage is based on 9,014,105 ordinary shares outstanding as of September 30, 2025, as advised to the reporting person. The filing relates to Ordinary Shares (CUSIP M7071P109), and identifies Gilboa as a citizen of Israel.
Nasus Pharma Ltd. filed a Form 6-K noting that on November 3, 2025, it made an updated corporate presentation available on its website. The presentation is furnished as Exhibit 99.1.
The company states the presentation is not a prospectus or offering document and does not constitute an invitation or offer to sell or solicit the purchase of any securities.
Nasus Pharma Ltd. reported that it expanded its long‑standing collaboration with AptarGroup to support development and potential commercialization of its NS002 intranasal Epinephrine program. The company and Aptar terminated their 2019 master services agreement and related work schedules, settling outstanding disputes, and replaced them with a new 2025 master services agreement focused on development, analytical, regulatory, and consulting services.
Under a new schedule of work, Aptar France will help develop, test, and prepare regulatory submissions for Nasus Pharma’s intranasal Epinephrine powder using Aptar’s Unit Dose Powder nasal delivery device. Nasus Pharma agreed to staged fees over three years, milestone payments on new drug application submission and approval, and royalties on commercial sales for seven years from first commercial sale. A separate supply agreement makes Aptar France the exclusive supplier of the device for Epinephrine products, with Nasus Pharma committing to purchase all of its requirements over an initial five‑year term, renewable for two additional years.
FAQ
What is the current stock price of Nasus Pharma Ltd. (NSRX)?
What is the market cap of Nasus Pharma Ltd. (NSRX)?
